Abstract

Objective: To compare the clinical efficacy of Clevira tablets in Human adult patients, with Mumps, HPV and Herpes zoster. Methods: An Open Label, Balanced, Randomized, Multi-Dose, Two-Treatment, Parallel, Comparative Phase III Clinical trial to determine the Safety and efficacy of Clevira Tablets. 20 Patients were enrolled for two types of treatments received. Treatment 1-Clevira Tablets for Mumps/HPV (n=10) and Treatment 2- Clevira Tablets for Herpes Zoster virus(n=10). Enrolment was based upon the diagnosis of Haematology, Biochemistry, Serology, RT-PCR and Chest X-Ray and inclusion and none of the exclusion criteria and included in the study. Results: All the patients demonstrated safety measures with respect to Blood pressure and Pulse rate. Also, statistically significant (p < 0.0001) improvement showed in temperature from baseline for Treatment 1- (101.89 ± 1.14) and at the end of the study period (97.84 ± 0.83), improvement showed in temperature from baseline for Treatment 2- (101.82 ± 1.15) and at the end of the study period (97.74 ± 0.88). Conclusion: The study demonstrated an expedited clinical cure with normal vital signs & haematological results which validated that Tablet Clevira is safe and efficacious in patients with Mumps/HPV and Herpes zoster virus. The data’s further entrusted that Clevira can be used in infected patients with Mumps/HPV and Herpes zoster, and relieve the signs and symptoms, with a rapid recovery, without any adverse side effects.